Swedbank AB Takes Position in Repligen Corporation $RGEN

Swedbank AB acquired a new stake in shares of Repligen Corporation (NASDAQ:RGEN) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 25,300 shares of the biotechnology company’s stock, valued at approximately $4,146,000.

A number of other hedge funds have also recently modified their holdings of RGEN. United Capital Financial Advisors LLC bought a new stake in shares of Repligen during the 3rd quarter valued at $368,387,000. Massachusetts Financial Services Co. MA purchased a new stake in shares of Repligen in the fourth quarter worth $199,176,000. Balyasny Asset Management L.P. increased its stake in shares of Repligen by 390.6% in the third quarter. Balyasny Asset Management L.P. now owns 767,239 shares of the biotechnology company’s stock worth $102,557,000 after purchasing an additional 610,837 shares in the last quarter. Congress Asset Management Co. increased its stake in shares of Repligen by 241.4% in the fourth quarter. Congress Asset Management Co. now owns 746,306 shares of the biotechnology company’s stock worth $122,290,000 after purchasing an additional 527,714 shares in the last quarter. Finally, Holocene Advisors LP increased its stake in shares of Repligen by 47.0% in the third quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company’s stock worth $184,077,000 after purchasing an additional 440,290 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $115.19 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. The firm has a fifty day moving average price of $117.78 and a 200 day moving average price of $140.26. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $175.77. The firm has a market cap of $6.50 billion, a price-to-earnings ratio of 127.99, a P/E/G ratio of 2.22 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The firm had revenue of $194.26 million during the quarter, compared to analyst estimates of $192.05 million. During the same quarter in the prior year, the business earned $0.39 earnings per share. Repligen’s revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, sell-side analysts expect that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of Repligen in a research note on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price objective for the company. Wells Fargo & Company reduced their price objective on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. Barclays increased their price objective on shares of Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Roth Mkm assumed coverage on shares of Repligen in a research note on Friday, April 17th. They issued a “buy” rating and a $160.00 price objective for the company. Finally, HC Wainwright increased their price objective on shares of Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, March 23rd. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and an average target price of $166.15.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.